
OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference
OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference OS Therapies a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADCs), has announced encouraging clinical data from its ongoing Phase 2b clinical trial of OST-HER2, a promising…